OKYO Pharma's Urcosimod Shows Long-Term Stability
Ticker: OKYO · Form: 6-K · Filed: Mar 31, 2025 · CIK: 1849296
Sentiment: neutral
Topics: drug-stability, pharmaceuticals, regulatory-update
TL;DR
OKYO Pharma's OK-101 drug is stable for 2.5+ years in ampoules, good news for patients.
AI Summary
On March 31, 2025, OKYO Pharma Ltd announced that its drug candidate, urcosimod (formerly OK-101), has demonstrated stability for over two and a half years when stored in single-use ampoules. This stability is crucial for the drug's administration to patients.
Why It Matters
This stability finding is important for the drug's shelf life and reliable delivery to patients, potentially impacting its commercial viability and regulatory approval.
Risk Assessment
Risk Level: low — The filing is a routine update on drug stability, not indicating new financial risks or significant operational changes.
Key Numbers
- 2.5 years — Drug Stability (Demonstrated stability of urcosimod in single-use ampoules.)
Key Players & Entities
- OKYO Pharma Ltd (company) — Registrant
- urcosimod (drug_candidate) — Drug being tested
- OK-101 (drug_candidate) — Previous name for urcosimod
- March 31, 2025 (date) — Date of announcement
FAQ
What is the significance of urcosimod's stability in single-use ampoules?
The stability of urcosimod for over two and a half years in single-use ampoules is significant for ensuring its efficacy and reliability when administered to patients.
What was urcosimod previously known as?
Urcosimod was formerly known as OK-101.
When did OKYO Pharma Ltd make this announcement?
OKYO Pharma Ltd announced this information on March 31, 2025.
What type of container was used to test the stability of urcosimod?
The stability of urcosimod was tested in single-use ampoules.
What is the primary business of OKYO Pharma Ltd?
OKYO Pharma Ltd is involved in the biological products industry, specifically focusing on products other than diagnostic substances.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 31, 2025 regarding OKYO Pharma Ltd (OKYO).